Clinical trial · Interventional
A Study of Epoetin Beta (NeoRecormon) in Participants With Solid Tumors
An Open-Label Study of the Safety Of NeoRecormon in Patients With Solid Tumors Being Treated With Platinum Capable of Inducing Anemia
NCT02554942CI-TRIAL-00024630completedPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the safety of subcutaneous (SC) epoetin beta (NeoRecormon) in adults with solid tumors being treated with platinum-based chemotherapy capable of inducing anemia. The anticipated time on study treatment is 16 weeks, and the target sample size is approximately 208 individuals.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epoetin beta | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Epoetin beta
- description
- Participants will receive weekly SC injection of epoetin beta (450 international units per kilogram \[IU/kg\]) for 16 weeks.
- interventionNames
- Drug: Epoetin beta
Primary outcomes (1)
- measure
- Incidence of adverse events
- timeFrame
- Up to 16 weeks
Secondary outcomes (1)
- measure
- Hemoglobin response rate index
- timeFrame
- Up to 16 weeks
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults at least 18 years of age * Presence of solid tumor(s) * Receiving platinum-based therapy capable of inducing anemia Exclusion Criteria: * Red blood cell transfusion within 7 days prior to study drug * Relevant acute or chronic bleeding requiring therapy within 3 months prior to study drug * Women who are pregnant or breastfeeding
References
Publications (0)
Data not yet available
No reference posted for this study.